

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:	Group Art Unit: 1614	
Jun Feng et al.	Examiner: Not Yet Assigned	
Serial No.: 10/809,638		
Filed: March 24, 2004	)	
For: DIPEPTIDYL PEPTIDASE INHIBITORS		

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Supplemental Information Disclosure Statement ("SIDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449, and copies of the literature and non-U.S. patent references are included

The items identified in this SIDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicants as such.

CERTIFICATE OF HAND DELIVERY					
I hereby certify that this paper (along with any refedelivered via hand delivery to the Commissioner for Alexandria, Virginia 22314.					
4/10/06	Name of Person Delivering Paper  Sohn Semillor				
Date of Deposit	Signature of Person Delivering Paper				

## INFORMATION DISCLOSURE STATEMENT FILING PROVISION:

This SIDS is believed to be time	ely in that it is being submitted under 37 CFR §
1.97(b), that is (1) within three months	of the filing date of the application, which is not a
continued prosecution application filed	under § 1.53(d); or (2) within three months of
entry of the national stage as set forth	in 37 CFR § 1.491; or (3) before the mailing of a
first Office action on the merits; or (4)	before the mailing of a first Office action after filing
a request for continued examination u	nder § 1.114. Thus, no fee is required.
requests that the Office	ned is in error in this regard, Applicant respectfully consider this SIDS as filed under 37 CFR § d charge the fee due under 37 CFR §1.17(p) to renced below.
requests that the Office	ned is in error in this regard, Applicant respectfully consider this SIDS as filed under 37 CFR § d a statement under 37 CFR § 1.97(e) is included uired.
This SIDS is being submitted up	nder 37 CFR § 1.97(c), that is after mailing of a
first Office action on the merits, but be	fore a Final Action under 37 CFR § 1.113 or a
Notice of Allowance under 37 CFR § 1	I.311.
The fee due under 37 CI	FR § 1.17(p) is submitted herewith.
required. In the event th or a Notice of Allowance Office consider the filing	FR § 1.97(e) is included below, thus no fee is at this SIDS is not received before a Final Action, then Applicant respectfully requests that the of these papers to be submitted under 37 CFR afeed due under 37 CFR § 1.17(p) to the deposit
under 37 CFR § 1.113 or a Notice of A	nder 37 CFR § 1.97(d), that is after a Final Action Allowance under 37 CFR § 1.311, but before t under 37 CFR § 1.97(e) is included below. The omitted herewith.
STATEMENT U	JNDER 37 CFR § 1.97(e):
	S was first cited in any communication from a
foreign patent office in a counterpart for	preign application not more than three months
prior to the filing of this SIDS.	
☐ No item contained in this SIDS	was cited in a communication from a foreign
patent office in a counterpart foreign a	pplication, and, to the knowledge of the person

signing this statement after making reasonable inquiry, no item of information contained in this SIDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this SIDS.

	PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:
	A check in the amount of is enclosed for the above fee(s).
	Please charge to Deposit Account No. 50-2256 for the above fee(s).
	Although Applicants do not believe any fees are required, the Commissioner is rized to charge any fees that may be required by the filing of these papers to da's Deposit Account No. 50-2256.
	Respectfully submitted,
	TAKEDA SAN DIEGO, INC.
Dated	By: Muthull R Brust  Mitchell R. Brustein  Beg. No. 38 394

Customer No. **32793**Takeda San Diego, Inc.
10410 Science Center Drive
San Diego, CA 92121
Tel: (858) 622-8528

Fax: (858) 550-0992

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE enwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 14

	Complete if Known	. )
Application Number	10/809,638	
Filing Date	March 24, 2004	
First Named Inventor	Jun FENG	
Group Art Unit	1614	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	DPP-IV-5004-C3	

		Document Number	-	Name of Patentee or Applicant of Cited		
Examiner Initials *	Cite No. <sup>1</sup>	Number - Kind Code² (if known)	Publication Date/ Issue Date MM-DD-YYYY	*Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear	
	AA	US 3,960,949	6/1/1976	Ahrens, Hanns et al.		
	AB	US 4,494,978	1/22/1985	Chan, David C. K.;		
	AC	US 4,935,493	6/19/1990	Bachovchin, William W. et al.		
	AD	US 5,366,862	11/22/1994	Venton, Duane L. et al.		
	AE	US 5,387,512	02/07/1995	Balani, Suresh K. et al.		
	AF	US 5,433,955	7/18/1995	Bredehorst, Reinhard et al.		
	AG	US 5,462,928	10/31/1995	Bachovchin, William W. et al.		
	AH	US 5,543,396	8/6/1996	Powers, James C. et al.		
	Al	US 5,601,986	2/11/1997	Takacs, Laszlo		
	AJ	US 5,614,379	3/25/1997	MacKellar, Warren C.		
	AK	US 5,624,894	4/29/1997	Bodor, Nicholas S.		
	AL	US 5,811,278	09/22/1998	Okamura, Hideki et al.		
	AM	US 5,811,281	09/22/1998	Quaroni, Andrea et al.		
	AN	US 5,814,460	9/29/1998	Venton, Duane L. et al.		
	AO	US 5,885,997	3/23/1999	Lohray, Vidya Bhushan et al.		
	AP	US 5,939,560	8/17/1999	Jenkins, Paul D. et al.		
	AQ	US 5,965,532	10/12/1999	Bachovchin, William W.		
•	AR	US 5,985,884	11/16/1999	Lohray, Vidya Bhushan et al.		
	AS	US 6,006,753	12/28/1999	Efendic, Suad		
	AT	US 6,011,155	1/4/2000	Villhauer, Edwin Bernard		
	AU	US 6,090,786	7/18/2000	Augustyns, Koen Jan Ludovicus et al.		
	AV	US 6,107,317	8/22/2000	Villhauer, Edwin Bernard		
	AW	US 6,110,949	8/29/2000	Villhauer, Edwin Bernard		
	AX	US 6,124,305	9/26/2000	Villhauer, Edwin Bernard		
•	AY	US 6,129,911	10/10/2000	Faris, Ronald A.		
	AZ	US 2001/0018210	8/30/2001	Bachovchin, William et al.		
	BA	US 2001/0031780	10/18/2001	Kanstrup, Anders et al.		
	ВВ	US 2001/0047078	11/29/2001	Chang, Yie-Hwa		
	ВС	US 6,172,081	1/9/2001	Damon, Robert		
	BD	US 6,184,020	2/6/2001	Blinkovsky, Alexander et al.		
	BE	US 6,201,132	3/13/2001	Jenkins, Paul D. et al.		
	BF	US 6,214,340	4/10/2001	Takeuchi, Tomio et al.		
	BG	US 6,235,493	5/22/2001	Bissell, Eugene R. et al.		
	вн	US 6,251,391	6/26/2001	Wilkinson, Randall Eugene et al.		

Examiner	Date	
Signature	Considered	,

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 144	PA/PTO			Complete if Known		
	•		Application Number	10/809,638		
INFORMATI	ON DIS	CLOSURE	Filing Date	March 24, 2004		
STATEMENT BY APPLICANT			First Named Inventor	Jun FENG		
			Group Art Unit	1614		
(use as ma	ny sheets as	necessary)	Examiner Name	Not Yet Assigned		
Sheet 2	of	14	Attorney Docket Number	DPP-IV-5004-C3		

ВІ	US 6,261,794	7/17/2001	Chang, Yie-Hwa	
BJ	US 6,265,551	7/24/2001	Duke-Cohan, Jonathan S. et al.	
BK	US 6,309,868	10/30/2001	Monod, Michel	
BL	US 6,310,069	10/30/2001	Lohray, Vidya Bhushan et al.	
ВМ	US 6,325,989	12/4/2001	Duke-Cohan, Jonathan S. et al.	
BN	US 2002/0006899	1/17/2002	Pospisilik, Andrew J. et al.	
ВО	US 2002/0019411	2/14/2002	Robl, Jeffrey A. et al.	
BP	US 2002/0037829	3/28/2002	Aronson, Peter S. et al.	
BQ	US 2002/0041871	4/11/2002	Brudnak, Mark A.	
BR	US 2002/0061839	5/23/2002	Scharpe, Simon Lodewijk et al.	
BS	US 2002/0071838	6/13/2002	Demuth, Hans-Ulrich et al.	
BT	US 2002/0077340	06/20/2002	Sulsky, Richard et al.	
BU	US 2002/0082292	6/27/2002	Sahoo, Soumya P. et al.	
BV	US 2002/0103242	8/1/2002	Sahoo, Soumya P. et al.	
BW	US 2002/0103384	8/1/2002	Kanstrup, Anders et al.	
вх	US 2002/0110560	8/15/2002	Demuth, Hans-Ulrich et al.	
BY	US 2002/0115843	08/22/2002	Oi, Steve et al.	
BZ	US 2002/0132979	9/19/2002	Chen, Wen-Tien	
CA	US 2002/0147130	10/10/2002	Huber, Brigitte T. et al.	
СВ	US 2002/0147157	10/10/2002	Connor, Gregory S.	
CC	US 2002/0155565	10/24/2002	Garin-Chesa, Pilar et al.	
CD	US 2002/016100	02/07/2002	Okabe, Toshiaki et al.	
CE	US 2002/0164759	11/7/2002	Travis, James et al.	
CF	US 2002/0165164	11/7/2002	Demuth, Hans-Ulrich et al.	
CG	US 2002/0183367	12/5/2002	Sulsky, Richard B. et al.	
CH	US 2002/0193390	12/19/2002	Villhauer, Edwin Bernard	
CI	US 2002/0198205	12/26/2002	Himmelsbach, Frank et al.	
CJ	US 6,335,429	1/1/2002	Cai, Sui Xiong et al.	
CK	US 6,337,069	1/8/2002	Grouzmann, Eric et al.	
CL	US 6,342,611	1/29/2002	Weber, Eckard et al.	·
СМ	US 6,355,614	3/12/2002	Wallner, Barbara P	
CN	US 6,395,767	5/28/2002	Robl, Jeffrey A. et al.	
СО	US 6,432,969	8/13/2002	Villhauer, Edwin Bernard	
CP	US 6,447,772	9/10/2002	Houston, Devin B.	
CQ	US 6,458,924	10/1/2002	Knudsen, Liselotte Bjerre et al.	·
CR	US 6,485,955	11/26/2002	Huber, Brigitte T. et al.	
CS	US 6,495,544	12/17/2002	Hansen, Jr., Donald W. et al.	
CT	US 2003/0008905	1/9/2003	Demuth, Hans-Ulrich et al.	

Examiner	Date	·
Signature	 Considered	;

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitut	e for form 1449A/P	то		Complete if Known		
				Application Number	10/809,638	
INFO	PRMATION	N DIS	CLOSURE	Filing Date March 24, 2004		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor Jun FENG		
				Group Art Unit	1614	
	(use as many s	heets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	3	of	14	Attorney Docket Number	DPP-IV-5004-C3	

CV		CU	US 2003/0027282	2/6/2003	Huber, Brigitte T. et al.	
CX US 2003/0055052 3/20/2003 Peters, Stefan et al.  CY US 2003/0060412 3/27/2003 Prouty, Walter Francis et al.  CZ US 2003/0060434 3/27/2003 Nielsen, Loretta et al.  DA US 2003/0067935 5/6/2003 Cheng, Peter T. et al.  DB US 2003/0087950 5/6/2003 DeNanteuil, Guillaume et al.  DC US 2003/008935 5/15/2003 Prouty, Walter Francis et al.  DD US 2003/008935 5/15/2003 Cheng, Peter T. et al.  DD US 2003/0096967 5/15/2003 DeNanteuil, Guillaume et al.  DE US 2003/0096866 5/22/2003 Cheng, Peter T. et al.  DE US 2003/0096866 5/22/2003 Cheng, Peter T. et al.  DF US 2003/009687 5/26/2003 Cheng, Peter T. et al.  DF US 2003/0096887 5/22/2003 Cheng, Peter T. et al.  DH US 2003/010553 5/26/2003 Cheng, Peter T. et al.  DH US 2003/010553 5/26/2003 Ervans, David Michael et al.  DH US 2003/010568 6/5/2003 Amelsberg, Andree et al.  DH US 2003/0119736 6/26/2003 Demuth, Hans-Ulrich et al.  DI US 2003/0119738 6/26/2003 Demuth, Hans-Ulrich et al.  DL US 2003/0119738 6/26/2003 Demuth, Hans-Ulrich et al.  DL US 2003/0130304 7/1/2003 Demuth, Hans-Ulrich et al.  DN US 2003/0130306 7/1/02/2003 Devasthale, Prailk et al.  DN US 2003/0130306 7/1/02/2003 Devasthale, Prailk et al.  DD US 2003/0139429 7/24/2003 Chenn, David Saul et al.  DD US 2003/0149071 8/7/2003 Gobbi, Luca Claudio et al.  DR US 2003/0149071 8/7/2003 Gobbi, Luca Claudio et al.  DN US 2003/0149071 8/7/2003 Jepnesen, Lone et al.  DV US 2003/016669 9/4/2003 Pryburg, David Albert et al.  DV US 2003/0181497 9/25/2003 Derwald, Florencio Zaragoza et al.  DV US 2003/018198 10/2/2003 Dorwald, Florencio Zaragoza et al.  DV US 2003/019518 10/2/2003 Dorwald, Florencio Zaragoza et al.  EB US 2003/019518 10/2/2003 Peschke, Bernd et al.  EB US 2003/019519 10/2/2003 Behrens, Carsten et al.		CV	US 2003/0040478	2/27/2003	Drucker, Daniel J. et al.	
CY US 2003/0060412 3/27/2003 Prouty, Walter Francis et al.  CZ US 2003/0060434 3/27/2003 Nielsen, Loretta et al.  DA US 2003/0067935 5/8/2003 Cheng, Peter T. et al.  DB US 2003/0087950 5/8/2003 DeNanteuil, Guillaume et al.  DC US 2003/0089935 5/15/2003 Fan, Tso-Hung et al.  DD US 2003/0098935 5/15/2003 Cheng, Peter T. et al.  DE US 2003/0098667 5/15/2003 Cheng, Peter T. et al.  DE US 2003/0098646 5/22/2003 Cheng, Peter T. et al.  DF US 2003/00986847 5/15/2003 Cheng, Peter T. et al.  DF US 2003/00986847 5/15/2003 Evans, David Michael et al.  DF US 2003/0105663 5/29/2003 Evans, David Michael et al.  DH US 2003/0105663 6/5/2003 Amelsberg, Andree et al.  DH US 2003/0103668 6/5/2003 Amelsberg, Andree et al.  DI US 2003/0109736 6/28/2003 Nestrop, Andree sendtz et al.  DL US 2003/0119736 6/28/2003 Demuth, Hans-Ulrich et al.  DL US 2003/0119738 6/28/2003 Demuth, Hans-Ulrich et al.  DL US 2003/0130281 7/10/2003 Demuth, Hans-Ulrich et al.  DN US 2003/0130281 7/10/2003 Devasthale, Pratik et al.  DN US 2003/0139429 7/24/2003 Cheng, David Saul et al.  DD US 2003/0139434 7/24/2003 Revision of Patrician Saul et al.  DP US 2003/0149071 8/7/2003 Ebdrup, Sork et al.  DR US 2003/0149071 8/7/2003 Ebdrup, Sore et al.  DN US 2003/0149071 8/7/2003 Ebdrup, Sore et al.  DV US 2003/0145669 9/4/2003 Fbdrup, David Albert et al.  DV US 2003/0174111 9/11/2003 Sobbi, Luca Claudio et al.  DV US 2003/017455 9/11/2003 Fbdrup, Soren et al.  DV US 2003/0186662 9/4/2003 Fbdrup, Soren et al.  DV US 2003/0186663 10/2/2003 Downald, Florencio Zaragoza et al.  DV US 2003/0186663 10/2/2003 Downald, Florencio Zaragoza et al.  EB US 2003/0195190 10/16/2003 Peschke, Bernd et al.  EB US 2003/0195263 10/23/2003 Robb, Jeffrey A. et al.  EB US 2003/019563 10/23/2003 Robb, Jeffrey A. et al.		cw	US 2003/0045464	3/6/2003	Hermeling, Ronald Norbert et al.	
CZ		СХ	US 2003/0055052	3/20/2003	Peters, Stefan et al.	
CZ		CY	US 2003/0060412	3/27/2003	Prouty, Walter Francis et al.	
DB	<u> </u>	CZ	US 2003/0060434	3/27/2003		
DC		DA	US 2003/0087935	5/8/2003	Cheng, Peter T. et al.	
DD		DB	US 2003/0087950	5/8/2003	DeNanteuil, Guillaume et al.	
DE		DC	US 2003/0089935	5/15/2003	Fan, Tso-Hung et al.	
DF		DD	US 2003/0092697	5/15/2003	Cheng, Peter T. et al.	
DG		DE	US 2003/0096846	5/22/2003	Cheng, Peter T. et al.	
DH US 2003/0103968 6/5/2003 Amelsberg, Andree et al.  DI US 2003/0105077 6/5/2003 Kanstrup, Anders Bendtz et al.  DI US 2003/0119736 6/26/2003 Demuth, Hans-Ulrich et al.  DK US 2003/0119738 6/26/2003 Niestroj, Andree et al.  DK US 2003/0125304 7/3/2003 Demuth, Hans-Ulrich et al.  DL US 2003/0125304 7/3/2003 Demuth, Hans-Ulrich et al.  DM US 2003/0130281 7/10/2003 Beehringer, Markus et al.  DN US 2003/0130306 7/10/2003 Devasthale, Pratik et al.  DN US 2003/0139429 7/24/2003 Cohen, David Saul et al.  DO US 2003/0139434 7/24/2003 Balkan, Bork et al.  DP US 2003/0139434 7/24/2003 Knudsen, Lotte Bjerre et al.  DR US 2003/0144006 7/31/2003 Knudsen, Lotte Bjerre et al.  DR US 2003/0149071 8/7/2003 Gobbi, Luca Claudio et al.  DS US 2003/0166662 9/4/2003 Fyrburg, David Albert et al.  DT US 2003/0166690 9/4/2003 Ebdrup, Soren et al.  DU US 2003/0171411 9/11/2003 Jeppesen, Lone et al.  DW US 2003/0181497 9/25/2003 Chen, Ping et al.  DW US 2003/0186963 10/2/2003 Dorwald, Florencio Zaragoza et al.  DY US 2003/0187254 10/2/2003 Dorwald, Florencio Zaragoza et al.  EA US 2003/0195188 10/16/2003 Behringer, Markus et al.  EB US 2003/0199528 10/23/2003 Robt, Jenes Carsten et al.  EC US 2003/0199563 10/23/2003 Robt, Anders B. et al.		DF	US 2003/0096857	5/22/2003	Evans, David Michael et al.	
DI US 2003/0105077 6/5/2003 Kanstrup, Anders Bendtz et al.  DJ US 2003/0119736 6/26/2003 Demuth, Hans-Ulrich et al.  DK US 2003/0119738 6/26/2003 Niestroj, Andre et al.  DL US 2003/0125304 7/3/2003 Demuth, Hans-Ulrich et al.  DM US 2003/0130281 7/10/2003 Boehringer, Markus et al.  DN US 2003/0130306 7/10/2003 Devasthale, Pratik et al.  DO US 2003/0139429 7/24/2003 Balkan, Bork et al.  DP US 2003/0139434 7/24/2003 Balkan, Bork et al.  DP US 2003/0139434 7/24/2003 Balkan, Bork et al.  DQ US 2003/0144206 7/31/2003 Knudsen, Lotte Bjerre et al.  DR US 2003/0166662 9/4/2003 Fryburg, David Albert et al.  DT US 2003/0166669 9/4/2003 Ebdrup, Soren et al.  DU US 2003/0171358 9/11/2003 Kodra, Janos Tibor et al.  DV US 2003/0171411 9/11/2003 Devasthale, Pratik et al.  DV US 2003/018497 9/25/2003 Chen, Ping et al.  DV US 2003/018499 11/2003 Dorwald, Florencio Zaragoza et al.  DY US 2003/0187254 10/2/2003 Boehringer, Markus et al.  EA US 2003/0195190 10/16/2003 Boehringer, Markus et al.  EB US 2003/0199528 10/23/2003 Robl, Jeffrey A. et al.  ED US 2003/0199563 10/23/2003 Robl, Jeffrey A. et al.  EE US 2003/0203946 10/30/2003 Behrens, Carsten et al.		DG	US 2003/0100563	5/29/2003	Edmondson, Scott D. et al.	
DJ	-	DH	US 2003/0103968	6/5/2003	Amelsberg, Andree et al.	
DK         US 2003/0119738         6/26/2003         Niestroj, Andre et al.           DL         US 2003/0125304         7/3/2003         Demuth, Hans-Ulrich et al.           DM         US 2003/0130281         7/10/2003         Boehringer, Markus et al.           DN         US 2003/0130306         7/10/2003         Devasthale, Pratik et al.           DO         US 2003/0139429         7/24/2003         Cohen, David Saul et al.           DP         US 2003/0139434         7/24/2003         Balkan, Bork et al.           DQ         US 2003/014206         7/31/2003         Bobi, Luca Claudio et al.           DR         US 2003/0149071         8/7/2003         Gobbi, Luca Claudio et al.           DS         US 2003/0166662         9/4/2003         Fryburg, David Albert et al.           DT         US 2003/0166690         9/4/2003         Ebdrup, Soren et al.           DU         US 2003/0171358         9/11/2003         Jeppesen, Lone et al.           DV         US 2003/0181497         9/25/2003         Chen, Ping et al.           DX         US 2003/0187254         10/2/2003         Dorwald, Florencio Zaragoza et al.           DY         US 2003/0195188         10/16/2003         Boehringer, Markus et al.           EB         US 2003/0195590 <td< td=""><td></td><td>DI</td><td>US 2003/0105077</td><td>6/5/2003</td><td>Kanstrup, Anders Bendtz et al.</td><td></td></td<>		DI	US 2003/0105077	6/5/2003	Kanstrup, Anders Bendtz et al.	
DL US 2003/0125304 7/3/2003 Demuth, Hans-Ulrich et al.  DM US 2003/0130281 7/10/2003 Boehringer, Markus et al.  DN US 2003/0130306 7/10/2003 Devasthale, Pratik et al.  DO US 2003/0139429 7/24/2003 Cohen, David Saul et al.  DP US 2003/0139434 7/24/2003 Balkan, Bork et al.  DQ US 2003/0144206 7/31/2003 Knudsen, Lotte Bjerre et al.  DR US 2003/0149071 8/7/2003 Gobbi, Luca Claudio et al.  DS US 2003/0166662 9/4/2003 Fbdrup, Soren et al.  DT US 2003/0166669 9/4/2003 Ebdrup, Soren et al.  DU US 2003/0171358 9/11/2003 Jeppesen, Lone et al.  DV US 2003/0171411 9/11/2003 Kodra, Janos Tibor et al.  DW US 2003/018497 9/25/2003 Chen, Ping et al.  DW US 2003/0186963 10/2/2003 Dorwald, Florencio Zaragoza et al.  DY US 2003/0197124 10/9/2003 Dorwald, Florencio Zaragoza et al.  DZ US 2003/0191112 10/9/2003 Dorwald, Florencio Zaragoza et al.  EA US 2003/0195189 10/16/2003 Boehringer, Markus et al.  EB US 2003/019589 10/23/2003 Kanstrup, Anders B. et al.  EC US 2003/0199563 10/23/2003 Behrens, Carsten et al.		DJ	US 2003/0119736	6/26/2003	Demuth, Hans-Ulrich et al.	
DM		DK	US 2003/0119738	6/26/2003	Niestroj, Andre et al.	
DN US 2003/0130306 7/10/2003 Devasthale, Pratik et al.  DO US 2003/0139429 7/24/2003 Cohen, David Saul et al.  DP US 2003/0139434 7/24/2003 Balkan, Bork et al.  DQ US 2003/0144206 7/31/2003 Knudsen, Lotte Bjerre et al.  DR US 2003/0149071 8/7/2003 Gobbi, Luca Claudio et al.  DS US 2003/0166662 9/4/2003 Fryburg, David Albert et al.  DT US 2003/0166690 9/4/2003 Ebdrup, Soren et al.  DU US 2003/0171358 9/11/2003 Jeppesen, Lone et al.  DV US 2003/0171411 9/11/2003 Kodra, Janos Tibor et al.  DW US 2003/0181497 9/25/2003 Chen, Ping et al.  DX US 2003/0187254 10/2/2003 Dorwald, Florencio Zaragoza et al.  DY US 2003/0191112 10/9/2003 Boehringer, Markus et al.  EA US 2003/0195188 10/16/2003 Peschke, Bernd et al.  EB US 2003/019563 10/23/2003 Robl, Jeffrey A. et al.  ED US 2003/0199563 10/23/2003 Robl, Jeffrey A. et al.  ED US 2003/0199563 10/23/2003 Robl, Jeffrey A. et al.		DL	US 2003/0125304	7/3/2003	Demuth, Hans-Ulrich et al.	
DO		DM	US 2003/0130281	7/10/2003	Boehringer, Markus et al.	
DP US 2003/0139434 7/24/2003 Balkan, Bork et al.  DQ US 2003/0144206 7/31/2003 Knudsen, Lotte Bjerre et al.  DR US 2003/0149071 8/7/2003 Gobbi, Luca Claudio et al.  DS US 2003/0166662 9/4/2003 Fryburg, David Albert et al.  DT US 2003/0166690 9/4/2003 Ebdrup, Soren et al.  DU US 2003/0171358 9/11/2003 Jeppesen, Lone et al.  DV US 2003/0171411 9/11/2003 Kodra, Janos Tibor et al.  DW US 2003/018497 9/25/2003 Chen, Ping et al.  DX US 2003/0186963 10/2/2003 Dorwald, Florencio Zaragoza et al.  DY US 2003/019112 10/9/2003 Perry, David A. et al.  DZ US 2003/019112 10/9/2003 Boehringer, Markus et al.  EA US 2003/0195180 10/16/2003 Peschke, Bernd et al.  EC US 2003/0199528 10/23/2003 Robl, Jeffrey A. et al.  ED US 2003/0203946 10/30/2003 Behrens, Carsten et al.		DN	US 2003/0130306	7/10/2003	Devasthale, Pratik et al.	
DQ US 2003/0144206 7/31/2003 Knudsen, Lotte Bjerre et al.  DR US 2003/0149071 8/7/2003 Gobbi, Luca Claudio et al.  DS US 2003/016662 9/4/2003 Fryburg, David Albert et al.  DT US 2003/0166690 9/4/2003 Ebdrup, Soren et al.  DU US 2003/0171358 9/11/2003 Jeppesen, Lone et al.  DV US 2003/0171411 9/11/2003 Kodra, Janos Tibor et al.  DW US 2003/0181497 9/25/2003 Chen, Ping et al.  DX US 2003/0186963 10/2/2003 Dorwald, Florencio Zaragoza et al.  DY US 2003/0187254 10/2/2003 Perry, David A. et al.  DZ US 2003/0191112 10/9/2003 Dorwald, Florencio Zaragoza et al.  EA US 2003/0195188 10/16/2003 Boehringer, Markus et al.  EB US 2003/0195190 10/16/2003 Peschke, Bernd et al.  EC US 2003/0199528 10/23/2003 Robl, Jeffrey A. et al.  ED US 2003/0203946 10/30/2003 Behrens, Carsten et al.		DO	US 2003/0139429	7/24/2003	Cohen, David Saul et al.	
DR US 2003/0149071 87/2003 Gobbi, Luca Claudio et al.  DS US 2003/0166662 9/4/2003 Fryburg, David Albert et al.  DT US 2003/0166690 9/4/2003 Ebdrup, Soren et al.  DU US 2003/0171358 9/11/2003 Jeppesen, Lone et al.  DV US 2003/0171411 9/11/2003 Kodra, Janos Tibor et al.  DW US 2003/0181497 9/25/2003 Chen, Ping et al.  DX US 2003/0186963 10/2/2003 Dorwald, Florencio Zaragoza et al.  DY US 2003/0187254 10/2/2003 Perry, David A. et al.  DZ US 2003/0191112 10/9/2003 Dorwald, Florencio Zaragoza et al.  EA US 2003/0195188 10/16/2003 Boehringer, Markus et al.  EB US 2003/0195190 10/16/2003 Peschke, Bernd et al.  EC US 2003/0199528 10/23/2003 Robl, Jeffrey A. et al.  ED US 2003/0199563 10/23/2003 Behrens, Carsten et al.		DP	US 2003/0139434	7/24/2003	Balkan, Bork et al.	
DS         US 2003/0166662         9/4/2003         Fryburg, David Albert et al.           DT         US 2003/0166690         9/4/2003         Ebdrup, Soren et al.           DU         US 2003/0171358         9/11/2003         Jeppesen, Lone et al.           DV         US 2003/0171411         9/11/2003         Kodra, Janos Tibor et al.           DW         US 2003/0181497         9/25/2003         Chen, Ping et al.           DX         US 2003/0186963         10/2/2003         Dorwald, Florencio Zaragoza et al.           DY         US 2003/0187254         10/2/2003         Perry, David A. et al.           DZ         US 2003/0191112         10/9/2003         Dorwald, Florencio Zaragoza et al.           EA         US 2003/0195188         10/16/2003         Boehringer, Markus et al.           EB         US 2003/0195190         10/16/2003         Peschke, Bernd et al.           EC         US 2003/0199528         10/23/2003         Kanstrup, Anders B. et al.           ED         US 2003/0199563         10/23/2003         Robi, Jeffrey A. et al.           EE         US 2003/0203946         10/30/2003         Behrens, Carsten et al.		DQ	US 2003/0144206	7/31/2003	Knudsen, Lotte Bjerre et al.	
DT US 2003/0166690 9/4/2003 Ebdrup, Soren et al.  DU US 2003/0171358 9/11/2003 Jeppesen, Lone et al.  DV US 2003/0171411 9/11/2003 Kodra, Janos Tibor et al.  DW US 2003/0181497 9/25/2003 Chen, Ping et al.  DX US 2003/0186963 10/2/2003 Dorwald, Florencio Zaragoza et al.  DY US 2003/0187254 10/2/2003 Perry, David A. et al.  DZ US 2003/0191112 10/9/2003 Dorwald, Florencio Zaragoza et al.  EA US 2003/0195188 10/16/2003 Boehringer, Markus et al.  EB US 2003/0195190 10/16/2003 Peschke, Bernd et al.  EC US 2003/0199528 10/23/2003 Robl, Jeffrey A. et al.  ED US 2003/0199563 10/23/2003 Behrens, Carsten et al.		DR	US 2003/0149071	8/7/2003	Gobbi, Luca Claudio et al.	
DU US 2003/0171358 9/11/2003 Jeppesen, Lone et al.  DV US 2003/0171411 9/11/2003 Kodra, Janos Tibor et al.  DW US 2003/0181497 9/25/2003 Chen, Ping et al.  DX US 2003/0186963 10/2/2003 Dorwald, Florencio Zaragoza et al.  DY US 2003/0187254 10/2/2003 Perry, David A. et al.  DZ US 2003/0191112 10/9/2003 Dorwald, Florencio Zaragoza et al.  EA US 2003/0195188 10/16/2003 Boehringer, Markus et al.  EB US 2003/0195190 10/16/2003 Peschke, Bernd et al.  EC US 2003/0199528 10/23/2003 Robl, Jeffrey A. et al.  ED US 2003/0199563 10/23/2003 Behrens, Carsten et al.		DS	US 2003/0166662	9/4/2003	Fryburg, David Albert et al.	
DV         US 2003/0171411         9/11/2003         Kodra, Janos Tibor et al.           DW         US 2003/0181497         9/25/2003         Chen, Ping et al.           DX         US 2003/0186963         10/2/2003         Dorwald, Florencio Zaragoza et al.           DY         US 2003/0187254         10/2/2003         Perry, David A. et al.           DZ         US 2003/0191112         10/9/2003         Dorwald, Florencio Zaragoza et al.           EA         US 2003/0195188         10/16/2003         Boehringer, Markus et al.           EB         US 2003/0195190         10/16/2003         Peschke, Bernd et al.           EC         US 2003/0199528         10/23/2003         Kanstrup, Anders B. et al.           ED         US 2003/0199563         10/23/2003         Robl, Jeffrey A. et al.           EE         US 2003/0203946         10/30/2003         Behrens, Carsten et al.		DT	US 2003/0166690	9/4/2003	Ebdrup, Soren et al.	
DW         US 2003/0181497         9/25/2003         Chen, Ping et al.           DX         US 2003/0186963         10/2/2003         Dorwald, Florencio Zaragoza et al.           DY         US 2003/0187254         10/2/2003         Perry, David A. et al.           DZ         US 2003/0191112         10/9/2003         Dorwald, Florencio Zaragoza et al.           EA         US 2003/0195188         10/16/2003         Boehringer, Markus et al.           EB         US 2003/0195190         10/16/2003         Peschke, Bernd et al.           EC         US 2003/0199528         10/23/2003         Kanstrup, Anders B. et al.           ED         US 2003/0199563         10/23/2003         Robl, Jeffrey A. et al.           EE         US 2003/0203946         10/30/2003         Behrens, Carsten et al.		DU	US 2003/0171358	9/11/2003	Jeppesen, Lone et al.	
DX         US 2003/0186963         10/2/2003         Dorwald, Florencio Zaragoza et al.           DY         US 2003/0187254         10/2/2003         Perry, David A. et al.           DZ         US 2003/0191112         10/9/2003         Dorwald, Florencio Zaragoza et al.           EA         US 2003/0195188         10/16/2003         Boehringer, Markus et al.           EB         US 2003/0195190         10/16/2003         Peschke, Bernd et al.           EC         US 2003/0199528         10/23/2003         Kanstrup, Anders B. et al.           ED         US 2003/0199563         10/23/2003         Robl, Jeffrey A. et al.           EE         US 2003/0203946         10/30/2003         Behrens, Carsten et al.		DV	US 2003/0171411	9/11/2003	Kodra, Janos Tibor et al.	
DY         US 2003/0187254         10/2/2003         Perry, David A. et al.           DZ         US 2003/0191112         10/9/2003         Dorwald, Florencio Zaragoza et al.           EA         US 2003/0195188         10/16/2003         Boehringer, Markus et al.           EB         US 2003/0195190         10/16/2003         Peschke, Bernd et al.           EC         US 2003/0199528         10/23/2003         Kanstrup, Anders B. et al.           ED         US 2003/0199563         10/23/2003         Robl, Jeffrey A. et al.           EE         US 2003/0203946         10/30/2003         Behrens, Carsten et al.		DW	US 2003/0181497	9/25/2003	Chen, Ping et al.	
DZ         US 2003/0191112         10/9/2003         Dorwald, Florencio Zaragoza et al.           EA         US 2003/0195188         10/16/2003         Boehringer, Markus et al.           EB         US 2003/0195190         10/16/2003         Peschke, Bernd et al.           EC         US 2003/0199528         10/23/2003         Kanstrup, Anders B. et al.           ED         US 2003/0199563         10/23/2003         Robi, Jeffrey A. et al.           EE         US 2003/0203946         10/30/2003         Behrens, Carsten et al.		DX	US 2003/0186963	10/2/2003	Dorwald, Florencio Zaragoza et al.	
EA US 2003/0195188 10/16/2003 Boehringer, Markus et al.  EB US 2003/0195190 10/16/2003 Peschke, Bernd et al.  EC US 2003/0199528 10/23/2003 Kanstrup, Anders B. et al.  ED US 2003/0199563 10/23/2003 Robi, Jeffrey A. et al.  EE US 2003/0203946 10/30/2003 Behrens, Carsten et al.		DY	US 2003/0187254	10/2/2003	Perry, David A. et al.	
EB US 2003/0195190 10/16/2003 Peschke, Bernd et al.  EC US 2003/0199528 10/23/2003 Kanstrup, Anders B. et al.  ED US 2003/0199563 10/23/2003 Robi, Jeffrey A. et al.  EE US 2003/0203946 10/30/2003 Behrens, Carsten et al.		DZ	US 2003/0191112	10/9/2003	Dorwald, Florencio Zaragoza et al.	
EC         US 2003/0199528         10/23/2003         Kanstrup, Anders B. et al.           ED         US 2003/0199563         10/23/2003         Robl, Jeffrey A. et al.           EE         US 2003/0203946         10/30/2003         Behrens, Carsten et al.		EA	US 2003/0195188	10/16/2003	Boehringer, Markus et al.	
ED US 2003/0199563 10/23/2003 Robl, Jeffrey A. et al.  EE US 2003/0203946 10/30/2003 Behrens, Carsten et al.		EB	US 2003/0195190	10/16/2003	Peschke, Bernd et al.	
EE US 2003/0203946 10/30/2003 Behrens, Carsten et al.		EC	US 2003/0199528	10/23/2003	Kanstrup, Anders B. et al.	
		ED	US 2003/0199563	10/23/2003	Robl, Jeffrey A. et al.	
EF US 2003/0216382 11/20/2003 Boehringer, Markus et al.			US 2003/0203946	10/30/2003	Behrens, Carsten et al.	
		EF	US 2003/0216382	11/20/2003	Boehringer, Markus et al.	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE				Application Number	10/809,638	
				Filing Date	March 24, 2004	
STA	<b>TEMEN</b>	T BY A	PPLICANT	First Named Inventor Jun FENG		
				Group Art Unit	1614	
	(use as many sheets as necessary)		Examiner Name	Not Yet Assigned		
Sheet	4	of	14	Attorney Docket Number	DPP-IV-5004-C3	

EG	US 2003/0216450	11/20/2003	Evans, David Michael et al.
EH	US 20030220345	11/27/2003	Hamby, James Marino et al.
EI	US 2003/0225102	12/4/2003	Sankaranarayanan, Alangudi
EJ	US 2003/0232761	12/18/2003	Hinke, Simon A. et al.
EK	US 6,521,644	2/18/2003	Broqua, Pierre
· EL	US 6,528,486	3/4/2003	Larsen, Bjarne Due et al.
EM	US 6,545,170	4/8/2003	Pitzele, Barnett S et al.
EN	US 6,548,529	4/15/2003	Robl, Jeffrey A. et al.
EO	US 6,555,519	4/29/2003	Washburn, William N.
EP	US 6,555,521	4/29/2003	Hermeling, Ronald Norbert et al.
EQ	US 6,559,188	5/6/2003	Gatlin, Marjorie Regan et al.
ER	US 6,573,096	6/3/2003	Chen, Wen-Tien
ES	US 6,573,287	6/3/2003	Sulsky, Richard B. et al.
ET	US 6,586,198	7/1/2003	Brown, Nancy J.
EU	US 6,608,038	8/19/2003	Caplan, Shari L. et al.
EV	US 6,617,340	9/9/2003	Villhauer, Edwin Bernard
EW	US 6,620,821	9/16/2003	Robl, Jeffrey A.
EX	US 6,627,636	· 9/30/2003	Robl, Jeffrey A.
EY	US 6,645,995	11/11/2003	Kanstrup, Anders et al.
EZ	US2004/0002495	1/1/2004	Sher, Philip et al.
FA	US2004/0002609	1/1/2004	Hulin, Bernard
FB	US2004/0006062	1/8/2004	Smallheer, Joanne M. et al.
FC	US2004/0009972	1/15/2004	Ding, Charles Z. et al.
FD	US2004/0009998	1/15/2004	Dhar, T. G. Murali et al.
FE	US2004/0034014	2/19/2004	Kanstrup, Anders Bendtz et al.
FF	US2004/0053369	3/18/2004	Abbott, Catherine Anne et al.
FG	US2004/0063935	4/1/2004	Yasuda, Kosuke
FH	US2004/0072874	4/15/2004	Sato, Nagaaki et al.
FI	US2004/0072892	4/15/2004	Fukushima, Hiroshi et al.
FJ	US2004/0077645	4/22/2004	Himmelsbach, Frank et al.
FK	US2004/0082497	4/29/2004	Evans, David Michael et al.
FL	US2004/0082607	04/29/2004	Oi, Satoru et al.
FM	US2004/0087587	5/6/2004	Himmelsbach, Frank et al.
FN	US2004/0092478	5/13/2004	Rothermel, John D. et al.
FO	US2004/0097510	5/20/2004	Himmelsbach, Frank et al.
FP	US2004/0106655	6/3/2004	Kitajima, Hiroshi et al.
FQ	US2004/0106656	6/3/2004	Ashton, Wallace T. et al.
FR	US2004/0106802	6/3/2004	Sankaranarayanan, Alangudi et al.

Examiner	Date	
Signature	Considered	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the complete by 35 0.3.0. 122 and 37 CFA 1.14. This collection is estimated to take 2 winds to complete including gathering, preparing, and submitting the complete this form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	Substitute for form 1449A/PTO		Complete if Known		
				Application Number	10/809,638
INFORMATION DISCLOSURE			CLOSURE	Filing Date	March 24, 2004
STA	TEMENT B	BY AI	PPLICANT	First Named Inventor Jun FENG	
				Group Art Unit	1614
	(use as many sheets as necessary)		Examiner Name	Not Yet Assigned	
Sheet	5	of	14	Attorney Docket Number	DPP-IV-5004-C3

	FS	U\$2004/0110817	6/10/2004	Hulin, Bernard	.
	FT	US2004/0116328	6/17/2004	Yoshikawa, Seiji et al.	
	FU	US2004/0132713	7/8/2004	Hulin, Bernard et al.	
	FV	US2004/0138148	7/15/2004	Fushimi, Nobuhiko et al.	
•	FW	US2004/0138214	7/15/2004	Himmelsbach, Frank et al.	· · ·
	FX	US2004/0138215	7/15/2004	Eckhardt, Matthias et al.	
	FY	US2004/0147434	7/29/2004	Ansorge, Siegfried et al.	
	FZ	US2004/0152192	8/5/2004	Bachovchin, William et al.	
	GA	US2004/0152745	8/5/2004	Jackson, Paul et al.	
	GB	US2004/0166125	8/26/2004	Himmelsbach, Frank et al.	
<u> </u>	GC	US2004/0167133	8/26/2004	Edmondson, Scott D. et al.	
1	GD	US2004/0167341	8/26/2004	Haffner, Curt Dale et al.	
	GE	US2004/0171104	9/2/2004	Blinkovsky, Alexander et al.	
	GF	US2004/0171848	9/2/2004	Haffner, Curt Dale et al.	
	GG	US2004/0176406	9/9/2004	Gobbi, Luca Claudio et al.	
· · · ·	GH	US2004/0176428	9/9/2004	Edmondson, Scott D et al.	
	GI	US2004/0180925	9/16/2004	Matsuno, Kenji et al.	
	GJ	US2004/0186153	9/23/2004	Yasuda, Nobuyuki et al.	
	GK	US2004/0198786	10/7/2004	Gretzke, Dirk et al.	
	GL	US2004/0209891	10/21/2004	Broqua, Pierre et al.	
	GM	US2004/0229820	11/18/2004	Bachovchin, William W. et al.	
	GN	US2004/0229848	11/18/2004	Demuth, Hans-Ulrich et al.	
	GO	US2004/0236102	11/25/2004	Brockunier, Linda et al.	
	GP	US2004/0242566	12/2/2004	Feng, Jun et al.	
	GQ	US2004/0242568	12/2/2004	Feng, Jun et al.	
	GR	US2004/0242636	12/2/2004	Haffner, Curt Dale et al.	
	GS	US2004/0242898	12/2/2004	Hulin, Bernard et al.	
	GT	US2004/0254167	12/16/2004	Biftu, Tesfaye et al.	
	GU	US2004/0254226	12/16/2004	Feng, Jun et al	
	GV	US2004/0259843	12/23/2004	Madar, David J. et al.	
	GW	US2004/0259870	12/23/2004	Feng, Jun et al.	
	GX	US2004/0259883	12/23/2004	Sakashita, Hiroshi et al.	
	GY	U\$2004/0259902	12/23/2004	Boehringer, Markus et al.	
	GZ	US2004/0259903	12/23/2004	Boehringer, Markus et al.	
	HA	US2004/0259919	12/23/2004	Magnin, David R. et al.	
	НВ	US 6,673,815	1/6/2004	Devasthale, Pratik et al.	
	HC	US 6,673,829	1/6/2004	Dorwald, Florencio Zaragoza et al.	
	HD	US 6,686,337	2/3/2004	Connor, Gregory S.	

	The second second	
Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	10/809,638	
INFO	RMATIO	N DIS	CLOSURE	Filing Date	March 24, 2004	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Jun FENG	
				Group Art Unit	1614	
	(use as many	sheets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	6	of	14	Attorney Docket Number	DPP-IV-5004-C3	

	<u> </u>			
HE	000,000,000	3/2/2004	Edmondson, Scott D. et al.	
THE	US 6,706,742	3/16/2004	De Nanteuil, Guillaume et al.	
HG	US 6,710,040	3/23/2004	Hulin, Bernard et al.	
НН	US 6,716,843	4/6/2004	De Nanteuil, Guillaume et al.	
HI	US 6,727,261	4/27/2004	Gobbi, Luca Claudio et al.	
HJ	US 6,727,271	4/27/2004	Cheng, Peter T. et al.	
НК	US 6,800,650	10/5/2004	Boehringer, Markus et al.	
HL	US 6,803,357	10/12/2004	Bachovchin, William A. et al.	
. HM	US 6,825,169	11/30/2004	Bachovchin, William W. et al.	
HN	US2005/0014732	1/20/2005	Gulve, Eric Arthur et al.	
НО	US2005/0014946	1/20/2005	Demuth, Hans-Ulrich et al.	
HP	US2005/0020574	1/27/2005	Hauel, Norbert et al.	
HQ	US2005/0026921	2/3/2005	Eckhardt, Matthias et al.	
HR	US2005/0032804	2/10/2005	Cypes, Stephen Howard et al.	
HS	US2005/0038020	2/17/2005	Hamann, Lawrence G. et al.	
нт	US2005/0043292	2/24/2005	Parker, Janice C. et al.	
ни	US2005/0043299	2/24/2005	Evans, David M. et al.	
HV	US2005/0058635	3/17/2005	Demuth, Hans-Ulrich et al.	
HW	US 6,861,440	3/1/2005	Boehringer, Markus et al.	
нх	US 6,867,205	3/15/2005	Boehringer, Markus et al.	

		FOREIGN PA	TENT DOCU	MENTS		
		Foreign Patent Document			Pages, Columns, Lines, Where	
Examiner Initials*		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	HY	DE 2361551A1	6/19/1975	BASF AG		
	HZ	DE 2500024A1	7/8/1976	BASF AG,		
	IA	EP 0505893	9/30/1992	MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG		
	IB	EP 0547514	6/23/1993	MERCK PATENT GESELLSCHAFT MIT BESCHRÄNKTER HAFTUNG		
	IC	EP 0574846	12/22/1993	MERCK PATENT GmbH		

		1870 m
Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitut	Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/809,638	
INFORMATION DISCLOSURE				Filing Date	March 24, 2004	
STA	<b>TEMEN</b>	T BY A	PPLICANT	First Named Inventor Jun FENG		
				Group Art Unit	1614	
	(use as many sheets as necessary)		Examiner Name	Not Yet Assigned		
Sheet	7	of	14	Attorney Docket Number	DPP-IV-5004-C3	

 		····		 
ID	EP 0657452	6/14/1995	MERCK PATENT GmbH	
IE	EP 0702013	3/20/1996	MERCK PATENT GmbH	
IF	GB 1441665A	7/7/1976	COMMONWEALTH SCIENTIFIC INDUSTRIAL RESEARCH ORGANISATION	
IG	WO 91/11457	8/8/1991	BUCKLEY, Douglas, I. Et al.	
IH	WO 95/15309	6/8/1995	FERRING B.V.	
11	WO 95/29691	11/9/1995	GEORGIA TECH RESEARCH CORPORATION	
IJ	WO 96/02667	2/1/1996	AMGEN INC.	
IK	WO 98/18763	5/7/1998	TANABE SEIYAKU CO., LTD.	
IL	WO 98/19998	5/14/1998	NOVARTIS AG	
IM	WO 98/50046	11/12/1998	TRUSTEES OF TUFTS COLLEGE	
IN	WO 98/51803	11/19/1998	NOVO NORDISK BIOTECH, INC.	
10	WO 99/02705	1/21/1999	SOCIETE DES PRODUITS NESTLE S.A.	
 IP	WO 99/17799	4/15/1999	TRUSTEES OF TUFTS COLLEGE ET AL.	•
IQ	WO 99/18856	4/22/1999	CYTOVIA, INC.	
IR	WO 99/28474	6/10/1999	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES	
IS	WO 99/46272	9/16/1999	FONDATECH BENELUX N.V.	
ΙΤ	WO 99/47152	9/23/1999	SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH	
IU	WO 99/62914	12/9/1999	POINT THERAPEUTICS, INC.	
IV	WO 00/10549	3/2/2000	POINT THERAPEUTICS, INC.	
IW	WO 00/20416	4/13/2000	GANTE, Helga	
IX	WO 00/40583	. 7/13/2000	MERCK PATENT GMBH	
ΙΥ	WO 00/43366	7/27/2000	KIRIN BEER KABUSHIKI KAISHA	
ΙZ	WO 00/56296	9/28/2000	FERRING BV	
JA	WO 00/56297 -	9/28/2000	FERRING B.V.	
JB	WO 01/16301	3/8/2001	TUFTS UNIVERSITY	

and the same of th	
Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO					Complete if Known	
·				Application Number	10/809,638	
INFOF	RMATIC	on dis	CLOSURE	Filing Date	March 24, 2004	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Jun FENG	
				Group Art Unit .	1614	
(6	(use as many sheets as necessary)			Examiner Name	Not Yet Assigned	
Sheet	8	of	14	Attorney Docket Number	DPP-IV-5004-C3	

JC	WO 01/19866	3/22/2001	THE UNIVERSITY OF SYDNEY	
JD	WO 01/40180	6/7/2001	FERRING BV	
JE	WO 01/55105	8/2/2001	NOVO NORDISK A/S	
JF	WO 01/62266	8/30/2001	NOVO NORDISK A/S	
JG	WO 01/68603	9/20/2001	BRISTOL-MYERS SQUIBB CO.	
· JH	WO 01/72290	10/4/2001	PROBIODRUG GESELLSCHAFT FÜR ARZNEIMITTELFORSCHUNG MBH	
· · JI	WO 01/74299	10/11/2001	THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK	
'n	WO 01/79206	10/25/2001	SUMITOMO PHARMACEUTICALS COMPANY, LIMITED	
JK	WO 01/81304	11/1/2001	FERRING BV	
JL	WO 01/81337	11/1/2001	FERRING B.V.	
JM	WO 01/89569	11/29/2001	INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH IMTM	
JN	WO 01/94597	12/13/2001	PROZYMEX A/S	
JO	WO 02/04610	1/17/2002	BAYER AKTIENGESELLSCHAFT	
JP	WO 02/051836	7/4/2002	KYOWA HAKKO KOGYO CO., LTD	
JQ	WQ 02/053170	7/11/2002	INSTITUT FÜR MEDIZINTECHNOLOGIE MAGDEBURG GMBH (IMTM	
JR	WO 02/059301	8/1/2002	K.U. LEUVEN RESEARCH AND DEVELOPMENT	
JS	WO 02/059343	8/1/2002	VANDERBILT UNIVERSITY	
JT	WO 02/062764	8/15/2002	TAKEDA CHEMICAL INDUSTRIES, LTD.	
JU	. WO 02/066627	8/29/2002	BAYER AKTIENGESELLSCHAFT	
JV	WO 02/068420	9/6/2002	BOEHRINGER INGELHEIM PHARMA KG	
JW	WO 02/076450	10/3/2002	MERCK & CO., INC.	
JX	WO 02/083128	10/24/2002	BRISTOL-MYERS SQUIBB COMPANY	
JY	WO 02/08931	1/31/2002	TEN SQUARE	
JZ	WO 02/092127	11/21/2002	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	
КА	WO 02/096357	12/5/2002	BRISTOL-MYERS SQUIBB COMPANY	

Examiner .	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute	e for form 1449A/PTO	)			Complete if Known	
				Application Number	10/809,638	
INFO	RMATION	DIS	CLOSURE	Filing Date	March 24, 2004	
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	Jun FENG	
				Group Art Unit	1614	
	(use as many she	ets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	9	of	14	Attorney Docket Number	DPP-IV-5004-C3	

	КВ	WO 02/14271	2/21/2002	WELFIDE CORPORATION	
	кс	WO 02/20804	3/14/2002	PROZYMEX A/S	
· · · · · · · · · · · · · · · · · · ·	KD	WO 02/26703	4/4/2002	PROLIFIX LIMITED	
	KE	WO 02/28742	4/11/2002	JOHANSSON, Thomas	
	KF	WO 02/30890	4/18/2002	TANABE SEIYAKU CO., LTD.	
	КG	WO 02/30891	4/18/2002	TANABE SEIYAKU CO., LTD.	
	КН	WO 02/31134	4/18/2002	FERRING BV	
	KI	WO 02/34900	5/2/2002	THE UNIVERSITY OF SYDNEY	
	KJ	WO 02/38541	5/16/2002	TAISHO PHARMACEUTICAL CO.,	
	-	WO 02/38742	5/16/2002	LTD. THE UNIVERSITY OF GEORGIA	
	KK			RESEARCH FOUNDATION, INC.	
	KL	WO 03/000180	1/3/2003	MERCK & CO., INC.	
	КМ	WO 03/000250	1/3/2003	FERRING BV	
	KN	WO 03/002530	1/9/2003	SMITHKLINE BEECHAM CORPORATION	
	ко	WO 03/002531	1/9/2003	SMITHKLINE BEECHAM	
	<del></del>	WO 03/002553	1/9/2003	CORPORATION SMITHKLINE BEECHAM	
1	KP			CORPORATION	
	KQ	WO 03/004496	1/16/2003	NOVO NORDISK A/S	
	KR	WO 03/004498	1/16/2003	MERCK & CO., INC.	
	кs	WO 03/010197	2/6/2003	GENSET S.A.	
	кт	. WO 03/010314	2/6/2003	GENSET S.A.	
<u> </u>	KU	WO 03/011807	2/13/2003	NOVO NORDISK A/S	
<b>—</b> —	ΚV	WO 03/011814	2/13/2003	NOVO NORDISK A/S	
	кw	WO 03/011834	2/13/2003	NOVO NORDISK A/S	
	кх	WO 03/011892	2/13/2003	THE U.S. GOVERNMENT as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	
	KY	. WO 03/014318	2/20/2003	GENZYME CORPORATION	
	KZ	WO 03/015775	2/27/2003	PROBIODRUG AG	
	LA	WO 03/017936	3/6/2003	YALE UNIVERSITY	
	LB	WO 03/024942	3/27/2003	MITSUBISHI PHARMA CORPORATION	

(Fina)	Date	
Examiner		
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reterence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in tot in conformance and it considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation is attached.

2 Applicant's unique citation is estimated to take 2 hours to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO					Complete if Known	
				: Application Number	10/809,638	
INF	FORMATIO	N DIS	CLOSURE	Filing Date	March 24, 2004	
ST	<b>ATEMENT</b>	BY A	PPLICANT	First Named Inventor	Jun FENG	
				Group Art Unit	1614	
	(use as many	sheets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	t 10	of	14	Attorney Docket Number	DPP-IV-5004-C3	ノ

				110110 1100001014 1/0	
	LC	WO 03/024965	3/27/2003	NOVO NORDISK A/S	
	LD	WO 03/035067	5/1/2003	FERRING B.V.	
	LE	WO 03/037327	5/8/2003	F. HOFFMANN-LA-ROCHE AG	
	LF	WO 03/038123	5/8/2003	NOVARTIS AG	
	LG	WO 03/040114	5/15/2003	BRISTOL-MYERS SQUIBB COMPANY	
	LH	WO 03/051848	6/26/2003	FERRING BV	
	LI	WO 03/053330	3/7/2003	ASTRAZENECA AB	
	W	WO 03/055881	7/10/2003	F. HOFFMANN-LA ROCHE AG	
	LK	WO 03/057144	7/17/2003	GUILFORD PHARMACEUTICALS	
	LL	WO 03/057666	7/17/2003	GUILFORD PHARMACEUTICALS	
	LM	WO 03/065983	8/14/2003	MERCK & CO., INC.	
	LN	WO 03/068748	8/21/2003	F. HOFFMANN-LA ROCHE AG	
	LO	WO 03/068757	8/21/2003	F. HOFFMANN-LA ROCHE AG	
		WO 03/072197	9/4/2003	PFIZER PRODUCTS INC.	
<del></del>	LP	WO 03/074500	9/12/2003	SANOFI-SYNTHELABO	
	LQ	WO 03/076393	9/18/2003	NOVARTIS AG	
	LR	WO 03/077935	9/25/2003	IMTM INSTITUT FÜR	
	LS	WO 03/07/933	3/23/2000	MEDIZINTECHNOLOGIE MAGDEBURG GMBH,	
	LT	WO 03/080070	10/2/2003	NOVARTIS AG	
	LU	WO 03/080633	10/2/2003	NIPPON KAYAKU KABUSHIKI KAISHA	
	LV	WO 03/082817	10/9/2003	MERCK & CO., INC.	
	LW	WO 03/082859	10/9/2003	NOVARTIS AG	
-		WO 03/084940	10/16/2003	SANKARANARAYANAN, Alangudi	
	LX	WO 03/101449	12/11/2003	PFIZER PRODUCTS INC.	
	LY	WO 03/101958	12/11/2003	PFIZER PRODUCTS INC.	
	LZ	WO 03/104207	12/18/2003	MERCK & CO., INC.	
	MA		12/18/2003	MERCK & CO., INC.	<del>                                     </del>
	мв	WO 03/104208			
	мс	WO 03/104229	12/18/2003	EISAI CO., LTD.	

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformance and in considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation is attached.

2 Application of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any including gathering, preparing, and submitting the complete application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

2 Application of the trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449A/	PTO			Complete if Known
				Application Number	10/809,638
INFO	DRMATIO	N DIS	CLOSURE	Filing Date	March 24, 2004
STA	STATEMENT BY APPLICANT			First Named Inventor	Jun FENG
				Group Art Unit	1614
	(use as many	sheets as	necessary)	Examiner Name	Not Yet Assigned
Sheet	T 11	of	14	Attorney Docket Number	DPP-IV-5004-C3

			•	
,	MD	WO 03/106456	12/24/2003	SANOFI-SYNTHELABO
1	ME	WO 04/002535	1/8/2004	HORMOS MEDICAL CORPORATION
,	MF	WO 04/002986	1/8/2004	BANYU PHARMACEUTICAL CO., LTD.
	MG	WO 04/004655	1/15/2004	BRISTOL-MYERS SQUIBB COMPANY
,	мн	WO 04/004661	1/15/2004	POINT THERAPEUTICS, INC.
	мі	WO 04/004665	1/15/2004	BRISTOL-MYERS SQUIBB COMPANY
1	MJ	WO 04/007446	1/22/2004	YAMANOUCHI PHARMACEUTICAL CO., LTD.
	мк	WO 04/007468	1/22/2004	MERCK & CO., INC.
	ML	WO 04/011640	2/5/2004	TANABE SEIYAKU CO., LTD.
	мм	WO 04/014860	2/19/2004	TAKEDA CHEMICAL INDUSTRIES, LTD.
ı	MN	WO 04/018467	3/4/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
	мо	WO 04/018468	3/4/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
	мР	WO 04/018469	3/4/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
	ма	WO 04/020407	3/11/2004	TAISHO PHARMACEUTICAL CO., LTD.
	MR	WO 04/024184 .	3/25/2004	TAKEDA CHEMICAL INDUSTRIES, LTD.
	мѕ	WO 04/026822	4/1/2004	ABBOTT LABORATORIES
	мт	WO 04/028524	4/8/2004	EISAI CO., LTD.
	мU	WO 04/031175	4/15/2004	BANYU PHARMACEUTICAL CO., LTD.
	м٧	WO 04/032836	4/22/2004	MERCK & CO., INC.
, '	MW	WO 04/032861	4/22/2004	BRISTOL-MYERS SQUIBB COMPANY
	мх	WO 04/033455	4/22/2004	NOVO NORDISK A/S
	MY	WO 04/037169	5/6/2004	MERCK & CO., INC.  BRISTOL-MYERS SQUIBB
	MZ	WO 04/037181	5/6/2004	COMPANY
	NA	WO 04/041795	5/21/2004	GUILFORD PHARMACEUTICALS INC.
	NB	WO 04/043940	5/27/2004	MERCK & CO., INC.
	NC	WO 04/046106	6/3/2004	PFIZER PRODUCTS INC.,

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reterence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer. If O Roy 1450 Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitut	e for form 1449/	VPTO		Complete if Known		
				Application Number	10/809,638	
INFC	PRMATIC	ON DIS	CLOSURE	Filing Date	March 24, 2004	
STA	TEMENT	BY A	PPLICANT	First Named Inventor	Jun FENG	
				Group Art Unit	1614	
(use as many sheets as necessary)				Examiner Name	Not Yet Assigned	
Sheet	12	of	14	Attorney Docket Number	DPP-IV-5004-C3	

ND	WO 04/048352	6/10/2004	FUJISAWA PHARMACEUTICAL CO., LTD.	
NE NE	WO 04/050022	6/17/2004	MERCK & CO., INC.	
. NF	WO 04/050656	6/17/2004	EISAI CO., LTD.	
NG	WO 04/050658	6/17/2004	BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG	
NH	WO 04/052850	6/24/2004	BRISTOL-MYERS SQUIBB COMPANY	
NI	WO 04/058266	7/15/2004	MERCK & CO., INC.	
NJ	WO 04/064778	8/5/2004	MERCK & CO. INC.	
NK	WO 04/067509	8/12/2004	SANWA KAGAKU KENKYUSHO CO., LTD.	
NL	WO 04/069162	8/19/2004	MERCK & CO., INC.	
NM	WO 04/071454	8/26/2004	GUILFORD PHARMACEUTICALS INC.	
NN	WO 04/075815	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH	
NO	WO 04/075891	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH	
NP	WO 04/076401	9/10/2004	AVENTIS PHARMA DEUTSCHLAND GMBH	·
NQ	WO 04/076433	9/10/2004	AIC	
NR	WO 04/076434	9/10/2004	AIC	
NS	WO 04/078777	9/16/2004	BIOREXIS PHARMACEUTICAL CORPORATION	
NT	WO 04/080958	9/23/2004	MERCK & CO. INC.	
NU	WO 04/083212	9/30/2004	MERCK & CO., INC.	
NV ·	WO 04/085661	10/7/2004	MERCK & CO., INC	
NW	WO 04/087053	10/14/2004	SYRRX, INC.	,
NX	WO 04/087650	10/14/2004	MERCK & CO. INC.	
NY	WO 04/087880	10/14/2004	BAYER PHARMACEUTICALS CORPORATION	
NZ	WO 04/089362	10/21/2004	NOVO NORDISK A/S	
OA	WO 04/096806	11/11/2004	SUMITOMO PHARMACEUTICALS CO. LTD.	
ОВ	WO 04/098625	11/18/2004	PROBIODRUG AG	<u> </u>
ос	WO 04/099134	11/18/2004	PROSIDION LTD.  FUJISAWA PHARMACEUTICAL	
OD	WO 04/099185	11/18/2004	CO. LTD.  TAISHO PHARMACEUTICAL CO.,	<u> </u>
OE	WO 04/101514	11/25/2004	LTD.	
OF	WO 04/103276	12/2/2004	MERCK & CO., INC.	
OG	WO 04/103993	12/2/2004	SYRRX, INC.	

Examiner	Date
Signature	Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

<sup>&</sup>quot;EXAMINEH: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this formation. comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitut	e for form 1449	A/PTO .		Complete if Known		
				Application Number	10/809,638	
INFC	PRMATI	on dis	CLOSURE	Filing Date	March 24, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Jun FENG	
				Group Art Unit	1614	
	(use as mar	ly sheets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	13	of	14	Attorney Docket Number	DPP-IV-5004-C3	

ОН	WO 04/110436	12/23/2004	MERCK & CO., INC.	
OI	WO 04/111041	12/23/2004	FUJISAWA PHARMACEUTICAL CO., LTD.	
Ol	WO 04/111051	12/23/2004	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	
ок	WO 04/112701	12/29/2004	MERCK & CO., INC.	
OL	WO 05/000846	1/6/2005	F.HOFFMANN-LA ROCHE AG	
ОМ	WO 05/003135	1/13/2005	MERCK & CO., INC.	
ON .	WO 05/011581	2/10/2005	MERCK & CO., INC.	
00	WO 05/012249	2/10/2005	BRISTOL-MYERS SQUIBB COMPANY	
OP	WO 05/019168	3/3/2005	PFIZER PRODUCTS INC.	
OQ	WO 2005/016911	2/24/2005	Syrrx, Inc.	

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
	OR	Database Crossfire Beilstein Institut zur Foerderung der Wissenchaften, Frankfurt am Main, DE; XP002335064. Database Accession no. 1447881 & J. HETEROCYCL.CHEM., Vol. 305,1972, pages 724-730.					
	os	Database Crossfire Beilstein Institut zur Foerderung der Wissenchaften, Frankfurt am Main, DE; XP002335065. Database Accession no. 1447134 & J.ORG.CHEM., Vol. 43, 1978, pages 4069-4074.					
	ОТ	Database Crossfire Beilstein Institut zur Foerderung der Wissenchaften, Frankfurt am Main, DE; XP002335066. Database Accession no. 386682 & J.CHEM.SOC., 1952, pages 4985-4990.					
	ΟU	Database Crossfire Beilstein Institut zur Foerderung der Wissenchaften, Frankfurt am Main, DE; XP002335067. Database Accession no. 389575 & CHEM.BER., Vol. 88, 1968, pages 106-109.					
	OV	Database Crossfire Beilstein Institut zur Foerderung der Wissenchaften, Frankfurt am Main, DE; XP002335068. Database Accession no. 472441 & YAKUGAKU ZASSHI, Vol. 88, 1968, pages 106-109.					
*	ow	Database Crossfire Beilstein Institut zur Foerderung der Wissenchaften, Frankfurt am Main, DE; XP002335069. Database Accession no. 1447840 & CHEM.BER., Vol. 101, No. 8, 1968, pages 2679-2689.					
	ох	Database Crossfire Beilstein Institut zur Foerderung der Wissenchaften, Frankfurt am Main, DE; XP002335070. Database Accession no. 1448669 & CHEM.BER., Vol. 101, No. 8, 1968, pages 2679-2689.					
	ОУ	Database Crossfire Beilstein Institut zur Foerderung der Wissenchaften, Frankfurt am Main, DE; XP002335071. Database Accession no. 4991064, J.CHEM.SOC.PERKIN TRANS.1, 1980, pages 1370-1380.					

Examiner	Date
	Considered
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in not in conformatice and in considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS Application.

1 Applicant's information is attached.

2 Applicant's unique citation to the information is attached.

2 Applicant's unique citation to the comment is not information in the information is attached.

2 Applicant's unique citation to the comment is not information in the information is attached.

3 Applicant's unique citation to the comment in the comment is not information in the comment in the com ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449A/PT(	)		Complete if Known		
				Application Number	10/809,638	
INFO	PRMATION	DIS	CLOSURE	Filing Date	March 24, 2004	
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	Jun FENG	
				Group Art Unit	1614	
N. Comments	(use as many she	ets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	14	of	14	Attorney Docket Number	DPP-IV-5004-C3	

oz	Database Crossfire Beilstein Institut zur Foerderung der Wissenchaften, Frankfurt am Main, DE; XP002335072. Database Accession no. 990008, J.PRAKT.CHEM., Vol. 315, 1973, pages 1166-1168.
PA	Database Crossfire Beilstein Institut zur Foerderung der Wissenchaften, Frankfurt am Main, DE; XP002335073. Database Accession no. 6219070, J.PRAKT.CHEM., Vol. 330, No. 2, 1988, pages 323-324.
PB	Database Crossfire Beilstein Institut zur Foerderung der Wissenchaften, Frankfurt am Main, DE; XP002335074. Database Accession no. 392446, J.HETEROCYCL.CHEM., Vol. 8, 1971, pages 367-371.
PC	Database Crossfire Beilstein Institut zur Foerderung der Wissenchaften, Frankfurt am Main, DE; XP002335075. Database Accession no. 4742608, J. PRAKT.CHEM., Vol. 333, No. 1, 1991, pages 149-151.
PD	Database Crossfire Beilstein Institut zur Foerderung der Wissenchaften, Frankfurt am Main, DE; XP002335076. Database Accession no. 490809, & ANGEW.CHEM., Vol. 84, 1972, page 1185.
PĒ	Database Crossfire Beilstein Institut zur Foerderung der Wissenschaften, Franfurt am Main, DE: XP002335063. Database-Accession no. 1525341 & J. HETEROCYCL.CHEM., Vol. 12, 1975, pages 683-687.
PF	GUPTA, A. et al.: "Fluorine containing Biologically Active Agents: Synthesis of some new Pyrimidine Derivatives" J.IND. CHEM.SOC., Vol. 71 1994, pages 635-636, XP000889664 compound 1
PG	Kesarwani, A. P. et al.: Solid-phase synthesis of quinazolin-(3H)-ones with three-point diversity, Tetrahedron Letters, Vol. 43, (2002) pp. 5579-5581.
PH	Rauchman, B.S. et al. "2,4—Diamino-5-benylpyrimidines and Analogues as antibacterial Agents", Journal of Med. Chem., Vol. 23, 1980, pages 384-391, XP002335048 Scheme II
	PA PB PC PD PE PF PG

Examiner	·	Date	
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Considered, include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.